Related Experiment Video
Updated: Aug 5, 2026
08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Exploring PIM1 Kinase as a Therapeutic Target: Mechanisms and Strategies in Cancer Treatment
Tingyu Zeng1, Huayong Liu1, Zhipan Li1
1Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
International Journal of Molecular Sciences
|July 28, 2026
Summary
Proviral integration site for Moloney murine leukemia virus 1 (PIM1) kinase is crucial in cancer progression and resistance. Targeting PIM1, alone or in combination therapies, offers promising new anti-cancer strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cancer is a leading cause of death globally, necessitating novel therapeutic approaches.
- Targeted therapies show promise but require identification of new targets.
- Proviral integration site for Moloney murine leukemia virus 1 (PIM1) kinase is implicated in tumor progression and poor prognosis.
Purpose of the Study:
- To systematically review PIM1's diverse mechanisms in promoting tumor progression.
- To evaluate PIM1 as a potential therapeutic target in cancer treatment.
- To propose future research directions for PIM1-targeted cancer therapy.
Main Methods:
- Systematic review and analysis of PIM1's roles in cancer.
- Evaluation of PIM1's involvement in various oncogenic processes.
- Assessment of PIM1's contribution to therapeutic resistance.
Main Results:
- PIM1 kinase drives tumor progression through multiple pathways, including cell death, cell cycle, DNA damage response, metastasis, stemness, metabolism, angiogenesis, and immune evasion.
- PIM1 is a significant factor in the development of resistance to anticancer therapies.
- PIM1 inhibition presents a viable therapeutic strategy.
Conclusions:
- PIM1 kinase is a critical mediator of tumor progression and therapeutic resistance.
- Combination strategies involving PIM1 inhibitors and agents targeting related pathways are recommended.
- Targeting PIM1 offers significant therapeutic potential for novel anti-cancer drug development.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...